CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular ...
The results of a newly reported study may offer scientists a strategy for mitigating the negative side effects associated with intravenous injection of nanoparticles used in medicine. The new approach ...
Initial study data indicate GEM103 can regulate complement activity in geographic atrophy secondary to dry age-related macular degeneration and has a tolerable safety profile, according to a press ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results